Benefits of rivastigmine on attention in dementia associated with Parkinson disease.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16301500.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. Significant benefits of rivastigmine over placebo were seen on all aspects of attention assessed: sustained attention, focused attention, consistence of responding, and central processing speed.
Medical subject headings
- Attention
- Dementia
- Neuroprotective Agents
- Parkinson Disease
- Phenylcarbamates